TABLE 1.
Baseline characteristics of participants in a randomized trial of IUD vs hormonal contraception in HIV-infected women
| Variable | Total (n = 599) | Hormonal (n = 303) | IUD (n = 296) |
|---|---|---|---|
| Age (y)* | 26.1 ± 4.9 | 25.9 ± 4.9 | 26.3 ± 4.9 |
| Married (n) | 536 (90%) | 272 (90%) | 264 (89%) |
| Total pregnancies (n)† | 2 (1–3) | 2 (1–3) | 2 (1–3) |
| Total living children (n)† | 2 (1–3) | 2 (1–3) | 2 (1–3) |
| Report at least 1 child death (n) | 166 (28%) | 81 (27%) | 85 (29%) |
| Years of schooling (n)* | 7.3 ± 3.0 | 7.4 ± 3.0 | 7.3 ± 3.0 |
| Any previous contraceptive use (n) | 367 (61%) | 186 (61%) | 181 (61%) |
| Previous oral contraceptive use (n) | 286 (48%) | 142 (47%) | 144 (49%) |
| Previous injectable use (n) | 96 (16%) | 47 (15.5%) | 49 (17%) |
| Previous IUD use (n) | 7 (1.2%) | 6 (2.0%) | 1 (0.3%) |
| Enrollment CD4+ count (cells/μL)* | 503 ± 259 | 493 ± 251 | 514 ± 266 |
| CD4+ count <200 cells/μL (n) | 60 (10%) | 30 (10%) | 30 (10%) |
| Enrollment hemoglobin level (g/dL)* | 11.7 ± 1.9 | 11.6 ± 1.9 | 11.7 ± 1.9 |
| Body mass index at enrollment (kg/m2)* | 24.1 ± 4.0 | 24.1 ± 4.0 | 24.2 ± 3.9 |
| Antibiotics for any cervicovaginal infection (n) | 269 (45%) | 141 (47%) | 128 (43%) |
| Cervicitis (n) | 96 (16%) | 50 (17%) | 46 (15%) |
| Candidiasis (n) | 10 (2%) | 8 (3%) | 2 (1%) |
| Trichomoniasis (n) | 101 (17%) | 53 (17%) | 48 (16%) |
| Bacterial vaginosis (n) | 62 (10%) | 30 (10%) | 32 (11%) |
*
Data are given as mean ± SD.
†
Data are given as median (interquartile range).